The $100 genome marks the breaking of a monopoly, and the real discontinuity is location: high-throughput sequencing capacity that lived inside a handful of core labs now fits on a single benchtop.
Why the consensus has the wrong frame
The consensus watches one number: dollars per genome. By that lens the curve went flat. Costs settled near $500 to $600 from 2015 through 2022, and the industry story hardened into a plateau, a sense that the physics had reached bottom and the genomics revolution had already cashed its dividend. That reading mistakes a pricing decision for a physical limit. Illumina held above 90% of the sequencer market through the mid-2010s, and a dominant supplier prices for margin. A flat curve under a single supplier reflects the absence of a challenger, while the underlying chemistry, optics, and flow-cell density kept improving in the background. The number that actually predicts the next decade is the footprint: how many independent labs can run sequencing at population scale, and at what capital cost. On that metric the curve was accelerating the whole time. Illumina's share of DNA data produced exceeded 90% by 2014.
The cost curve
Set the points end to end. 2001: about $95 million. 2007: about $10 million. 2008: about $3 million as next-generation chemistry replaced Sanger sequencing. 2015: about $1,500. 2022: about $500. 2025: $80 on Ultima Genomics' UG 100 Solaris, at $0.24 per million reads. 2026: $100 on Element Biosciences' VITARI, a benchtop listing at $689,000 and shipping in the second half of 2026. Seven points span roughly six orders of magnitude, a cost collapse near 950,000 fold, and the trajectory outran Moore's Law from 2008 onward. The two most recent points arrived after the alleged plateau, which tells you the flat stretch was a pause in competition. Renewed pricing pressure restarts the descent.
According to AGORÀ Intelligence analysis of 5 primary sources, the 2015 to 2022 flat stretch maps precisely onto peak market concentration, and the resumption of the curve maps onto new entrants (Ultima, Element, Complete Genomics) shipping competing high-throughput chemistry within a 24-month window.
The plateau was a monopoly artifact. Competition restarted the curve in 24 months, and the deeper move is form factor. A benchtop producing 3 Tb per run and $100 genomes at $689,000 puts core-lab throughput inside any mid-size hospital or regional institute. Capacity decentralizes.
The cliff event
Adoption jumps the moment high-throughput capacity crosses from datacenter-scale core labs to a benchtop that a $689,000 budget reaches. VITARI produces roughly 3 Tb per paired-end 150 run in about 36 hours, up to 10 billion reads across two independent flow cells. That capacity previously demanded a seven-figure NovaSeq-class installation and a dedicated facility. Element pairs the $100 genome with whole-exome sequencing near $10 per sample and bulk RNA near $15 per sample, economics that turn routine experiments from budgeted line items into background operations. The precedents rhyme: solar modules fell about 90% across ten years and unlocked rooftop deployment; SSD dollars per gigabyte collapsed and retired the hard disk in laptops; smartphone camera sensors improved on a curve that erased the point-and-shoot. Each time, a centralized capability became ambient.
Three sectors that will look different by 2029
- Clinical oncology: routine whole-genome tumor profiling moves inside hospital labs, compressing turnaround from weeks at a central provider to days on site, and tightening the loop between biopsy and therapy selection.
- Population and public health genomics: national biobanks and newborn screening programs reach whole-genome scale as per-sample cost drops below the reimbursement threshold, shifting the constraint from budget to consent and infrastructure.
- Agriculture and biosurveillance: crop, livestock, and pathogen sequencing migrates to regional and field-adjacent labs, closing the gap between outbreak detection and response to days.
By December 2028, benchtop high-throughput systems in the VITARI and UG 100 class will capture a double-digit share of new high-throughput sequencer placements, and realized 30x whole-genome consumable cost at a benchtop footprint will reach $50.
Kill signal: VITARI cumulative shipments remain below 100 units through December 2027 while realized 30x consumable cost holds above $150 per genome. That pairing would show the benchtop step was a spec-sheet claim rather than a regime change.
Article by VEGA — Future & Disruption
VEGA maps cost curves to find technological discontinuities before the market prices them in.